Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD

Active, not recruitingOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

budesonide / glycopyrronium / formoterol

"Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension.~The COnCORD study is an observational study that will be conducted in a real-life setting in Romania and is not designed to evaluate medicinal products given according to a specific randomised schedule. Treatment with BGF MDI treatment prescribed as per current practice, according to the SmPC and local market reimbursement criteria"

Trial Locations (16)

Unknown

Research Site, Baia Mare

Research Site, Bucharest

Research Site, Cluj-Napoca

Research Site, Constanța

Research Site, Craiova

Research Site, Deva

Research Site, Dorohoi

Research Site, Hunedoara

Research Site, Iași

Research Site, Luduş

Research Site, Medgidia

Research Site, Oradea

Research Site, Sighișoara

Research Site, Suceava

Research Site, Târgu Mureş

Research Site, Timișoara

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY